View All Podcasts  Subscribe

March 19 2019 Issue

Predictors of dementia misclassification when using brief cognitive assessments

Listen

March 12 2019 Issue

A multicentre comparison of MOG-IgG cell based assays

Listen

March 5 2019 Issue

The prevalence of MS in the United States: A population-based estimate using health claims data

Listen

February 26 2019 Issue

Quality Improvement in Neurology: Universal Neurology Quality Measurement Set Executive Summary

Listen

February 19 2019 Issue

Physical activity, common brain pathologies, and cognition in community-dwelling older adults

Listen

1.Physical activity, common brain pathologies, and cognition in community-dwelling older adults 

February 12 2019 Issue

Quality of Life Outcomes in Patients Presenting for Evaluation of Central Nervous System Tumors

Listen

1.Quality of Life Outcomes in Patients Presenting for Evaluation of Central Nervous System Tumors

2. [What’s Trending]: 'Landmark study’ shows brain cells revamp their DNA, perhaps sparking Alzheimer’s disease. In the first segment, Dr. Ted Burns talks with Dr. Irene Katzan about her paper on quality of life outcomes in patients presenting for evaluation of central nervous system tumors.

In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Jerold Chun on a 'Landmark study’ showing brain cells revamp their DNA, perhaps sparking Alzheimer’s disease.Dr. Ted Burns has served on scientific advisory boards for Argenx, Momenta, received travel funding or speaker honoraria from Argenx, Alexion and received support for consulting activities from UCB Pharma, CSL Behring, Momenta, Argenx. Dr. Irene Katzan has served on editorial boards for Stroke (American Stroke Association), 2014-present Editorial Board - Circulation: Cardiovascular Quality & Outcomes (American Heart Association) 2013 – present. Dr. Irene Katzan has received research from one commercial entity including Novartis Pharmaceuticals and received research support from the following government entity: Ohio Department of Health - Physician Lead for the Ohio Paul Coverdell Stroke Registry, 2007-2020. Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001).Dr. Jerold Chun reports no disclosures.

February 5 2019 Issue

Recommendations of the 2017 AAN Diversity Leadership Program

Listen

1. Reducing neurodisparity: Recommendations of the 2017 AAN Diversity Leadership Program

View All Podcasts  Subscribe

January 29 2019 Issue

Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement

Listen

1. Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement. 

January 22 2019 Issue

Aspirin Reduces Long Term Stroke Risk in Women with Prior Hypertensive Disorders of Pregnancy

Listen

1. Aspirin Reduces Long Term Stroke Risk in Women with Prior Hypertensive Disorders of Pregnancy

2. [What’s Trending]: Top-selling drug price hikes and patients bearing the cost

In the first segment, Dr. Andrew Southerland talks with Dr. Eliza Miller about her paper on aspirin reducing the long term stroke risk in women with prior hypertensive disorders of pregnancy. In the second part of the podcast, Dr. Ted Burns focuses his talk with Casey Ross on makers of top-selling drugs hiking prices and patients bearing the costs.DISCLOSURES: Dr. Eliza Miller has served on Editorial Boards for Stroke, Assistant Editor, InterSECT, 2017-2018. Dr. Eliza Miller Research Support, Government Entities including (1) NIH NINDS 5U10NS086728-05, Fellow, 2017-2018 (2) NIH NINDS U01 NS095869, Subsite PI, 2018 (3) NIH NCATS 5KL2TR001874-02, KL2 Scholar, 2018-2020 and she has received research support from Foundations and Societies including American Medical Association Foundation and Louis V. Gerstner Foundation. Casey Ross reports no disclosures.

January 15 2019 Issue

A score that predicts one year functional status in anti-NMDA receptor encephalitis patients.

Listen

1. A score that predicts one year functional status in anti-NMDA receptor encephalitis patients. 

January 8 2019 Issue

Development and validation of a score to detect paroxysmal atrial fibrillation after stroke

Listen

1. Development and validation of a score to detect paroxysmal atrial fibrillation after stroke. 

January 1 2019 Issue

Continuous EEG is Associated with Favorable Hospitalization Outcomes for Critically Ill Patients

Listen

1. Continuous EEG is Associated with Favorable Hospitalization Outcomes for Critically Ill Patients.

2. [What’s Trending]: Investigation of "generic" cartel.

In the first segment, Dr. Andy Schomer talks with Dr. Chloe Hill on the association between continuous EEG and favorable hospitalization outcomes for critically ill patients. In the second part of the podcast, Dr. Ted Burns focuses his interview with Christopher Rowland of the Washington Post on the investigation into a generic drug "cartel." Dr. Chloe Hill has served as an epileptologist for clinical procedures or imaging studies; and has received governmental research support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke. Dr. Ted Burns has served on the scientific advisory boards for Argenx and Momenta; has received funding for travel or speaker honoraria from Argenx and Alexion; has served on editorial boards as the Section Editor for Neurology Podcast and as Section Deputy Editor, Neurology Podcast; and has received support for consulting activities from UCB Pharma, CSL Behring, Momenta, and Argenx. Christopher Rowland is employed as a full-time reporter for the Washington Post.

View All Podcasts  Subscribe

December 18 2018 Issue

The ethical and philosophical implications of gene editing

Listen

1. The ethical and philosophical implications of gene editing.

2. [What’s Trending]: Scientific and societal impact gene editing

Dr. Jason Crowell talks with Dr. Josephine Johnston of the Hastings Center on the ethical and philosophical implications of gene editing. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Stefan Pulst on the scientific and societal impact of the recent first reported gene editing using the CRISPR technology. Dr. Jason Crowell reports no disclosures. Dr. Josephine M. Johnston has received honoraria for speaking or travel from The Hastings Center, the University of Toronto, Danbury Hospital, World Science festival, the Yale School of Medicine, the University of Pennsylvania Law School, the Royal Society of New Zealand, McGill University, Dalhousie University, and Queensland University of Technology; and has received foundation/society research support from the John Templeton Foundation. Dr. Clardy serves as the Podcast Section Editor for Neurology and has received research support from Western Institute for Biomedical Research (WIBR). Dr. Stefan Pulst has served on the editorial boards of Journal of Cerebellum, NeuroMolecular Medicine, Experimental Neurology, Neurogenetics, Nature Clinical Practice, Neurology, and as the Editor-in-Chief of Neurology: Genetics; holds numerous patents (for the following: Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Shwannomin-binding-proteins; Compositions and methods for spinocerebellar ataxia); has received publishing royalties from The Ataxias (Churchill Livingston, 2007), Genetics in Neurology (ANN Press, 2005), Genetics of Movement Disorders (Academic Press, 2003), Neurogenetics (Oxford University Press, 2000), Molecular Genetic Testing in Neurology, 2nd - 5th (AAN Press, 1996); has served as a consultant for Ataxion Therapeutics; has served on the speakers' bureau for Athena Diagnostics, Inc.; has received governmental research support from National Institutes of Health and the Clinical Research Consortium for Spincerebellar Ataxias; has received foundation/society research support for serving as a fellowship award mentor from National Ataxia Foundation; and has received license fee payments for technology or inventions from the Cedars-Sinai Medical Center.

December 11 2018 Issue

Body mass index, but not vitamin D status, is associated with brain volume change in MS

Listen

1. Body mass index, but not vitamin D status, is associated with brain volume change in MS

2. [What’s Trending]: preventing firearm injury

 In the first segment, Dr. Stacey Clardy talks with Dr. Ellen Mowry about her paper on the associations between body mass index and brain volume change in MS. In the second part of the podcast, Dr. Ted Burns focuses his interview with Dr. Christine Laine on preventing firearm injury. Dr. Clardy serves as the Podcast Section Editor for Neurology and has received research support from Western Institute for Biomedical Research (WIBR). Dr. Ellen Mowry has served on a liothyronine study Data and Safety Monitoring Board; serves on the editorial board of Frontiers in Neuroepidemiomology; has received royalties as an UptoDate chapter editor; has received commercial research support from Teva Neuroscience, Biogen Idec, Genzyme, and Sun Pharma; has received governmental research support from the Department of Defense; and has received foundation/society research support from the National Multiple Sclerosis Society and the Patient-Centered Outcomes Research Institute. 

December 3 2018 Issue

Patient-reported outcomes across cerebrovascular event types - more similar than different

Listen

1. Patient-reported outcomes across cerebrovascular event types - more similar than different 

2. [What’s Trending]: Genetic landscape of pediatric movement disorders and management implications.

 In the first segment, Dr. Andrew Southerland talks with Dr. Irene Katzan about her paper on patient-reported outcomes across cerebrovascular event types. In the second part of the podcast, Dr. Jeff Waugh focuses his interview with Dr. Saadet Andrews on the genetic landscape of pediatric movement disorders and management implications. DISCLOSURES: Dr. Southerland has severed on editorial boards for the Journal Neurology and is Section Editor for the Neurology Podcast. Dr. Katzan served on editorial boards for Stroke (American Stroke Association) and Circulation: Cardiovascular Quality & Outcomes (American Heart Association). Dr. Katzan has received funding for research support from Novartis Pharmaceuticals and research support from the Ohio Department of Health - Physician Lead for the Ohio Paul Coverdell Stroke Registry, 2007-2020. Dr. Waugh was employed by Children's Hospital Boston, Resident in Pediatric Neurology, 2009-2015. Dr.Saadet Andrews served on a scientific advisory board for non-profit data safety board member for a research study at The Hospital for Sick Children (2015-2017), a Commercial: Epileptic encephalopathy scientific board meeting attended in December 2017, organized by BioMarin, and a Commercial: Advisor cost effectiveness of ERT (March 2018) Commercial: Advisory board and speaker for homocysteine and betaine treatment (December 2017). Dr. Andrews received funding for travel from BioMarin (Epileptic encephalopathy scientific board meeting attended as invited speaker in December 2017) and was paid honorarium and travel-expenses. Dr. Andrews served on editorial boards for Non-profit: Journal of Pediatric Genetics Editorial Board Member (2015-present) and received research support from industry funding (2015-2016) for prevalence of mucopolysaccharidosis if rheumatology and NCV patients.

View All Podcasts  Subscribe

November 27 2018 Issue

Early predictors of mortality in parkinsonism and Parkinson’s disease: a population-based study

Listen

1. Early predictors of mortality in parkinsonism and Parkinson’s disease: a population-based study 

2. [What’s Trending]: Data from the Largest Natural History Study of Stiff Person Syndrome.

  In the first segment, Dr. Jeffery Ratliff talks with Dr. David Bäckström about his paper on Early predictors of mortality in parkinsonism and Parkinson’s disease. In the second part of the podcast, Dr. Jeffery Ratliff focuses his interview with Marinos Dalakas on Stiff Person Syndrome. DISCLOSURES:Dr. Jeff Ratliff has received speaker honoraria from Teva and US WorldMeds LLC; is the deputy editor for the Neurology Podcast; has been a consultant for UCB Pharmaceuticals, US WorldMeds LLC, Medscape, and Retrophin Inc; and has served on speakers' bureaus for Teva and US WorldMeds LLC. Dr. David C Bäckström holds patents for chemical compounds that may be developed as treatments for premenstrual dysphoric disorder, but has not received any personal compensation for the patents. Dr. David C Bäckström has received Research Support from Swedish Medical Research Council, grant number (K2013- 62X-15224-10-4) and unrestricted grant for Parkinson's disease research and has received foundation and societies research support from Erling Persson Foundation, Umeå University, Västerbotten County Council, King Gustaf V and Queen Victoria Freemason Foundation, Swedish Parkinson Foundation, Kempe Foundation, and Swedish Parkinson’s Disease Association. Dr. Marinos Dalakas serves the CIDP steering committee for Novartis and on DSMB for Baxalta and Octapharma, has received funding or served as a travel speaker honoraria for Merck/Serono, OCTAPHARMA, PFIZER AG. Dr. Marinos Dalakas has served on editorial board including Neurology, editorial board (5 years, not compensated), BMC Neurology (Section Editor, 5 years not compensated), Acta Myologica, editorial board (5 years, not compensated), Acta Neurologica Scandinavica editorial board (5 years, not compensated), and Therapeutic Advances in Neurology (Associate Editor; 4 years, compensated). Dr. Marinos Dalakas consultancies include work with Therapath, Baxter, Octapharma, CSL, Dysimmune Diseases Foundation and he has received research and institutional support from Thomas Jefferson University Neurology department or to Neuroimmunology Unit, University of Athens Medical School for research and education from: Merck-Serono, Genzyme, Novartis, Guillain-Barre/CIDP Foundation, Dysimmune diseases Foundation, CSL, Biogen and Newfactor.

November 20 2018 Issue

Devastating neurological injuries in the Syrian War

Listen

1. Devastating neurological injuries in the Syrian War

2. [What’s Trending]: Standards for Neurologic Critical Care Units: A Statement for Healthcare Professionals from The Neurocritical Care Society.

 In the first segment, Dr. Jason Crowell talks with Dr. Maher Saqqur and Yasmeen El Hajj Abdallah about neurological injuries in the Syrian War. In the second part of the podcast, Dr. Andrew Schomer focuses his interview with Dr. Asma Moheet on Standards for Neurologic Critical Care Units. DISCLOSURES: Drs. Jason Crowell, Maher Saqqur, Asma Moheet, and Andrew Schomer report no disclosures. Yasmeen El Hajj Abdallah reports employment with Shoppers Drugmart Pharmacy as pharmacy student for less than one year.

November 13 2018 Issue

Gray matter differences in patients with functional movement disorders

Listen

1. Gray matter differences in patients with functional movement disorders

2. [What’s Trending]: Recovery of Over-Ground Walking after Chronic Motor Complete Spinal Cord Injury.

 In the first segment, Dr. David Lapides talks with Dr. Carine Maurer about her paper on gray matter differences in patients with functional movement disorders. In the second part of the podcast, Dr. Alex Menze focuses his interview with Claudia Angeli on recovery of over-ground walking after chronic motor complete spinal cord injury. Dr. David Lapides reports no disclosures. Dr. Carine Maurer received research support from NIH, Intramural Research Program and academic research support from Stony Brook University School of Medicine. Dr. Maurer has done consultancy work for Gerson Lehrman Group. Dr. Alex Menze reports no disclosures. Dr. Claudia Angeli reports no disclosures.

November 6 2018 Issue

Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US

Listen

1. Featured Article Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US

2. [What’s Trending]: Acute flaccid myelitis

In the first segment, Dr. Nick Brenton talks with Dr. Kristen Krysko about her paper on therapies for pediatric multiple sclerosis. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Kenneth Tyler on acute flaccid myelitis. DISCLOSURES: Dr. Nick Brenton does not report any disclosures.Dr. Kristen Krysko received fellowship support from he National Multiple Sclerosis Society.Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Tyler serves as an Associate Editor for Journal of Neurovirology and Neurology Today; serves as an editorial board member for Annals of Neurology, Apoptosis, JAMA Neurology, Experimental Neurology, Journal of Infectious Disease, Microbial Pathogenesis, Virology, Neurology ALL Current; serves on the scientific advisory board for DNAtrix (DSMB, active), LPath (DSMB)(completed), and PML Consortium (Scientific Advisory Board, completed); is a consultant for Hoffman La Roche; receives royalties from the publication of the books: Handbook of Clinical Neurology and Harrison's Principles & Practices of Internal Medicine; receives research support from Taiga Biotechnologies and the NIH/NIAID, 1R01 NS101208, PI, 2018-2022, Dept. of Veterans Affairs Merit Grant (BX000963, Role: PI, 2017-21), NIH/NINDS, (5R21NS103186, PI, 2017-2019); and serves as Officer (Treasurer) and Member Board of Directors American Neurological Association (ANA)- Uncompensated.

October 30 2018 Issue

Quality improvement in neurology: Epilepsy Quality Measurement Set 2017

Listen

October 23 2018 Issue

"'Is there a neurologist on this flight?' An update"

Listen

1. Featured Article: “‘Is there a neurologist on this flight?’ An update”

2. What’s Trending: paraneoplastic neuronal intermediate filament autoimmunity

Dr. Jason Crowell talks with Dr. Joseph Sirven about his NCP paper entitled “‘Is there a neurologist on this flight?’ An update.” In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Andrew McKeon on paraneoplastic neuronal intermediate filament autoimmunity.

DISCLOSURES:Dr. McKeon has patent applications pending: Septin 5 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; his Consultancies include Grifols Medimmune Euroimmun with no personal compensation received for these activities; he has received research support from Medimmune, Inc Euroimmun Grifols. Dr. Sirven has served on scientific advisory boards Commercial- Advisory role for Eisai, Upsher - Smith Non- profit- Epilepsy Foundation, AAN, FAA; has has funding for travel or speaker honoraria for Epilepsy Foundation- travel; has served on Editorial Boards for Epilepsy.com; has published royalties for Up to Date 2010 Clinical Neurology of the Older Adult, LWW, 2008; has completed projects for Medscape; is on the Board of Directors of the American Brain Foundation; has supported research for Government Entities, NINDS sub Investigator and supported research for Foundations and Societies, Epilepsy Foundation. Dr. McKeon has patent applications pending: Septin 5 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; his Consultancies include Grifols Medimmune Euroimmun with no personal compensation received for these activities; he has received research support from Medimmune, Inc Euroimmun Grifols.

October 16 2018 Issue

Primary angiitis of the CNS and reversible cerebral vasoconstriction syndrome: A comparative study​

Listen

1. Featured Article: Primary angiitis of the CNS and reversible cerebral vasoconstriction syndrome: A comparative study

2. What’s Trending: Cannabis and chronic neuropathic pain

Dr. Andy Southerland talks with Dr. Anne Ducros about her paper on primary angiitis of the CNS and reversible cerebral vasoconstriction syndrome. In the second part of the podcast, Dr. Heather Harle focuses her interview with Dr. Haggai Sharon on the use of cannabis analgesia in chronic neuropathic pain.

DISCLOSURES: Dr. Ducros has served on scientific Advisory Boards for Novartis, Eli Lilly, and TEVA;has served on editorial boards for Cephalalgia: Associate Editor, Headache: editorial advisory board member, Journal of Headache and Pain: editorial advisory board member. Dr. Sharon reports no disclosures. Dr. Southerland has served on editorial boards for Journal Neurology, Section Editor Neurology Podcast.

Patents Intellectual property unrelated to current work: U.S. Patent Application No. 14/910,890 (iTREAT study) U.S. Provisional Patent Application No. 62/620,096 (BANDIT study). Dr. Southerland's consultancies include National Stroke Association - helped develop website for resources regarding telestroke and teleneurology, Research Support, Commercial Entities. Dr. Southerland's Edwards Lifesciences include perform neurological assessments for the PARTNER clinical trials of transcatheter aortic valve replacement. Dr. Southerland's Research Support, Government Entities include Stroke Hyperglycemia Insulin Network Effort (SHINE) NINDS/NIH U-01 NS 069498, Health Resources Services Administration - Evidence based tele-emergency network grant (RURAL EQUIT-E Project) HRSA G01RH27869, and NHLBI/NINDS - Cardiothoracic Surgical Trials Network (CTSN) - performed neurological assessments in conjunction with the neuroprotection trial of aortic valve replacement. Dr. Southerland's Research Support, Foundations and Societies include American Heart Association-American Stroke Association National Clinical Research Program, Cervical Artery Dissection Expression (CADEX) AHA 3CRP141400001, American Academy of Neurology - Education Research Grant, American Board of Psychiatry and Neurology - Faculty Fellowship Award. Dr. Southerland's legal proceedings include Legal Expert Review - perform expert review, on behalf of the UVA University Physician's Group, pertaining to stroke and vascular neurology questions for both plaintiff and defense cases.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

October 9 2018 Issue

Nusinersen in spinal muscular atrophy type 1 patients older than 7 months: a cohort study

Listen

1. Featured Article: Neurology: Clinical Practice -- Presentation and management of community onset vs. hospital onset first seizures

2. What’s Trending: Acute viral encephalitis

Dr. Katherine Zarroli talks with Dr. Emma Foster about her paper comparing the presentation and management of patients with community- and hospital-onset first seizures attending the same hospital. In the second part of the podcast, Dr. Stacey Clardy and Dr. Kenneth Tyler review the diagnosis and treatment of acute viral encephalitis.

DISCLOSURES: Dr. Zarroli reports no disclosures. Dr. Foster has received research support from National Health and Medical Research Council (NHMRC) Medical / Dental Research Postgraduate Scholarship, APP1150482, CIA, funding 2018-2020 and Royal Australasian College of Physicians (RACP) Research entry scholarship, 2018. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Tyler serves as an Associate Editor for Journal of Neurovirology and Neurology Today; serves as an editorial board member for Annals of Neurology, Apoptosis, JAMA Neurology, Experimental Neurology, Journal of Infectious Disease, Microbial Pathogenesis, Virology, Neurology ALL Current; serves on the scientific advisory board for DNAtrix (DSMB, active), LPath (DSMB)(completed), and PML Consortium (Scientific Advisory Board, completed); is a consultant for Hoffman La Roche; receives royalties from the publication of the books: Handbook of Clinical Neurology and Harrison's Principles & Practices of Internal Medicine; receives research support from Taiga Biotechnologies and the NIH/NIAID, 1R01 NS101208, PI, 2018-2022, Dept. of Veterans Affairs Merit Grant (BX000963, Role: PI, 2017-21), NIH/NINDS, (5R21NS103186, PI, 2017-2019); and serves as Officer (Treasurer) and Member Board of Directors American Neurological Association (ANA)- Uncompensated.

October 2 2018 Issue

Nusinersen in spinal muscular atrophy type 1 patients older than 7 months: a cohort study

Listen

1. Featured Article: Nusinersen in spinal muscular atrophy type 1 patients older than 7 months: a cohort study

2. What’s Trending: MRI-guided thrombolysis for stroke with unkown time of onset (WAKE-UP study)

Dr. Ted Burns talks with Dr. Laurent Servais about his paper on safety and efficacy of nusinersen treatment in patients with SMA type 1 older than 7 months. In the second part of the podcast, we are featuring a discussion with Dr. Jim Siegler and Dr. Christian Gerloff on the results of the WAKE-UP stroke trial.

DISCLOSURES: Dr. Servais has served as scientific consultant in the S.A.B of Roche, Biomarin, aTyr Pharma, Dynacure, Biogen, Bamboo, Sarepta, and Avexis; has received speaker honoraria gave lecture sponsored by Biomarin, Biogen, and Sarepta; holds patents as co-inventor of the Moviplate device, and of Actimyo; has consulted for Bamboo therapeutics, Pfizzer, Anagenesis, Avexis, and Dynacure; has received research support from NHS, Valerion, Dynacure, Avexis, Biogen, Roche, FP7 programs Skip and Scope, Université de Liège, and Association Française contre les Myopathies.

September 25 2018 Issue

Antiepileptic Drug Clearances during Pregnancy and Clinical Implications for Women with Epilepsy

Listen

1. Featured Article: Antiepileptic Drug Clearances during Pregnancy and Clinical Implications for Women with Epilepsy

2. What’s Trending: AAN Position Statement: Lawful physician-hastened death

Dr. Derek Bauer talks with Dr. Paula Emanuela Voinescu about her paper on antiepileptic drug (AED) clearances during pregnancy and the relationship between AED serum concentration and seizure frequency. In the second part of the podcast, we are featuring a discussion with Dr. Jason Crowell and Dr. James Russell on the recent AAN position statement regarding lawful physician-hastened death.

DISCLOSURES: Dr. Voinescu has received speaker honoraria from SUNOVION, and has received research support from American Academy of Neurology, Susan Spencer Clinical Training Fellowship. Dr. Russell has received funding for travel from the Mexican Academy of Neurology; receives publishing royalties from Neuromuscular Disorders (McGraw-Hill, 2nd ed, 2015) and honorarium for a published article in Continuum Peripheral Neuropathy 2017; has received compensation for market research interviews regarding ALS therapeutics; and has received reimbursement for record review of medical legal proceedings without testimony or document authorship. All other participants report no disclosures.

September 18 2018 Issue

Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trial

Listen

1. Featured Article: Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trial

2. What’s Trending: Emerging therapies for spinal muscular atrophy and Duchenne muscular dystrophy

Dr. Jeff Ratliff talks with Dr. Alberto Benussi about his paper on cerebellar anodal and spinal cathodal transcranial direct current stimulation as a therapeutic approach for reducing symptoms in patients with neurodegenerative ataxia. In the second part of the podcast, we are featuring a discussion with Dr. Ted Burns and Stat reporter Adam Feuerstein on two emerging therapies for spinal muscular atrophy and Duchenne muscular dystrophy.

DISCLOSURES: Dr. Ratliff has received speaker honoraria from Teva and US WorldMeds LLC; is the deputy editor for the Neurology Podcast; has been a consultant for UCB Pharmaceuticals, US WorldMeds LLC, Medscape, and Retrophin Inc; and has served on speakers' bureaus for Teva and US WorldMeds LLC. Dr. Burns has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. Benussi and Mr. Feuerstein report no disclosures.

September 4 2018 Issue

Practice guideline recommendations summary: Disorders of consciousness

Listen

1. Practice guideline recommendations summary: Disorders of consciousness

2. What's Trending: Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus (ICHD-3)

Dr. Jeff Burns talks with Dr. Joseph Giacino about the AAN Guideline update on disorders of consciousness. In the second part of the podcast, we are featuring a discussion with Dr. Jason Crowell and Dr. Joel Dudley in which they talk about the detection of human herpesvirus genes in in a large cohort patients with Alzheimer disease.

DISCLOSURES: Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001). Dr. Giacino has served on the scientific advisory board for the Traumatic Brain Injury Model Systems National Data and Statistical Center (federal agency); serves on the editorial board for Journal of Head Trauma Rehabilitation; serves as Director of the Spaulding Rehabilitation Network Disorders of Consciousness Program; has received research support from the U.S. Department of Defense, (Co-Investigator, W81XWH-11- 2-0210; Co-Investigator, W81XWH- 08-2-0159; Co-PI, W81XWH-14-2-0176), National Institute on Disability and Rehabilitation Research, (PI, H133A120085; site PI, 90DP0060; PI 4, 90DPTB0011), National Institutes of Health (Co-PI, 1U01NS086090-01; Co-PI, UH3NS095554), James S. McDonnell Foundation, and the The Barbara Epstein Foundation, Inc; and served as expert witness in legal proceedings for DeCorato Cohen Sheehan & Federico. Dr. Crowell and Dr. Dudley report no disclosures.

August 28 2018 Issue

How Early Can We Diagnose Alzheimer’s Disease (And Is It Sufficient)?

Listen

1. How Early Can We Diagnose Alzheimer’s Disease (And Is It Sufficient)?

2. What's Trending: Updates to the International Classification of Headache Disorders (ICHD-3)

Dr. Stacey Clardy talks with Dr. Ronald Petersen about his paper on Alzheimer disease diagnosis. In the second part of the podcast, Dr. Tesha Monteith focuses her interview with Dr. Jes Olesen on what's new in the 3rd edition of the International Classification of Headache Disorders (ICHD-3). The full ICHD-3 can be found at https://www.ichd-3.org/wp-content/uploads/2018/01/The-International-Classification-of-Headache-Disorders-3rd-Edition-2018.pdf

DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Petersen receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003); has consulted for Roche Incorporated, Merck, Genentech, Biogen, and GE Healthcare (presentation); and has received research support from the National Institute on Aging (U01-AG006786, P50-AG016574, U01-AG024904, U01 AG016976). Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Olesen has consulted for Jannsen Pharmaceutical Products and served on speakers' bureaus for Allergan. 

August 21 2018 Issue

Silent infarct is a risk factor for infarct recurrence in adults with sickle cell anemia

Listen

1. Featured Article: Silent infarct is a risk factor for infarct recurrence in adults with sickle cell anemia

2. What’s Trending: Neuropalliative Care: Priorities to move the field forward

Dr. Justin Sattin talks with Dr. Lori Jordan about her paper on silent infarct and the risk of infarct recurrence in adults with sickle cell anemia. In the second part of the podcast, Dr. Maisha Robinson focuses her interview with Dr. Claire Creutzfeldt on neuropalliative care.

DISCLOSURES: Dr. Jordan serves on the editorial boards of the Journal of Child Neurology, Pediatric Neurology and Stroke; and has received research support from Dr. Creutzfeldt has received research support from NINDS (K23 NS099421-01A1) and Cambia Health Foundation's Sojourn Scholars Program. Dr. Sattin and Dr. Robinson reports no disclosures.

August 14 2018 Issue

Safety and efficacy of plasma exchange in pediatric transverse myelitis

Listen

1. Neurology® Clinical Practice: Safety and efficacy of plasma exchange in pediatric transverse myelitis

2. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA (POINT study)

Dr. Stacey Clardy talks with Dr. Benjamin Greenberg about his paper on therapeutic plasma exchange in a cohort of pediatric transverse myelitis patients. Next, Will Rondeau interviews Dr. Clay Johnston about findings from the POINT study on clopidogrel and aspirin in acute ischemic stroke.

DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Greenberg has received travel funding from the Transverse Myelitis Association; has filed has filed patents on the use of antibody biology in multiple sclerosis; has consulted for Novartis, Alexion, and EMD Serono; and has received research support from Medimmune, Chugai, Medday, Genentech, NIH (RO1 NS071463), Unviersity of Texas Southwestern, Guthy Jackson Foundation, PCORI, Transverse Myelitis Association, and the National MS Society. Dr. Johnston has received travel reimbursements from the National Academies of Sciences, US News, Austin Chamber of Commerce, Johns Hopkins, UT Health Science Center, University of Utah Medical School, Medtronic, Astrazeneca, University of Rochester NY, and Duke University; has received research support from AstraZeneca, NIH/NCATS (UL1 RR024131), UCSF Clinical-Translational Science Institute, and NIH/NINDS (U01 NS062835-01A1, U01 NS062835). Mr. Rondeau reports no disclosures. 

No CME this week: Interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program.

August 7 2018 Issue

Diagnosing Cerebral Ischemia with Door-to-Thrombolysis Times Below 20 Minutes

Listen

1. Diagnosing Cerebral Ischemia with Door-to-Thrombolysis Times Below 20 Minutes

2. What’s Trending: Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke

Dr. Jimmy Berthaud speaks with Dr. Perttu Lindsberg about his paper on the accuracy and consequences of rapid stroke diagnostics in a neurological emergency department. In the second segment of the podcast, Dr. Kevin Barrett interviews Dr. Bruce Campbell about the EXTEND-IA TNK trial of tenecteplase for patients with ischemic stroke.

DISCLOSURES: Dr. Berthaud reports no disclosures. Dr. Lindsberg serves as Assistant Editor for the medical journal DUODECIM; serves as chairman of the ad hoc committee on Current Therapy Guidelines in Stroke for the Finnish Medical Society; and has recieved research support for Helsinki University Hospital District, the Sigrid Jusélius Foundation, the Jane and Aatos Erkko Foundation, and the Signe and Ane Gyllenberg Foundation. Dr. Barrett has received research support from Axovant Sciences, Inc., the Virginia Center of Alzheimer's and Related Diseases, and the Department of Defense. Dr. Campbell serves on the editorial board for Stroke Stroke; served as PI of the EXTEND-IA trial, partially funded by unrestricted grant from Medtronic; and has received research support from the National Health and Medical Research Council of Australia (GNT1111972 2016-2019) and the Heart Foundation, Australia.

July 31 2018 Issue

Organic solvents and MS susceptibility: Interaction with MS risk HLA genes

Listen

1. Organic solvents and MS susceptibility: Interaction with MS risk HLA genes

2. AAN 2018 Controversies in Neurology plenary: Andrea Leigh Haller and David Perez discuss primary caregivers for functional disorder patients

Dr. Stacey Clardy talks with Dr. Anna Hedström about her paper on exposure to organic solvents and the associated risk of developing multiple sclerosis, followed by a discussion with Dr. Alberto Espay, Dr. Andrea Leigh Haller, and Dr. David Perez on who should be the primary caregivers for functional disorder patients. The second interview was originally recorded at the AAN Annual Meeting in Los Angeles.

DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Drs. Hedström, Leigh Haller, and Perez report no disclosures. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; and receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation, and the NIH.

July 24 2018 Issue

Non-invasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study

Listen

1. Non-invasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study

2. AAN 2018 Hot Topics plenary: Michael Wilson discusses metagenomics for diagnosing CNS infections

Dr. Teshamae Monteith talks with Dr. Cristina Tassorelli about her paper on vagus nerve stimulation for treating migraine, follwed by a discussion with Dr. Stacey Clardy and Dr. Michael Wilson on next-generation sequencing and diagnosing meningitis and encephalitis. The second interview was originally recorded at the AAN Annual Meeting in Los Angeles.

DISCLOSURES: Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Tassorelli has served on scientific advisory boards for Allergan Inc., ElectroCore LLC, Eli-Lilly and Company, Novartis, Teva Pharmaceutical Industries Ltd; has received funding for travel or speaker honoraria from Novartis, Allergan Inc, and Teva Pharmaceutical Industries Ltd; serves on editorial boards for Journal of Headache and Pain and Frontiers in Neurology; has consulted for Allergan Inc. and Eli Lilly and Company; has received research support from Eli Lilly and Company, Novartis, Teva Pharmaceuticals, ElectroCore, and the Italian Ministry of Health; and serves as Chairman of the Committee for the Guidelines of Clinical Trials of the International Headache Society. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Wilson has received research support from NIH/National Center of Advancing Translational Science (NCATS), Clinical and Translational Science Institute (CTSI), and the American Brain Foundation Clinical Research Training Fellowship.

July 17 2018 Issue

Longitudinal analysis of impulse control disorders in Parkinson disease

Listen

1. Featured Article: Longitudinal analysis of impulse control disorders in Parkinson's disease

2. What's Trending: Frontiers in Neuroscience plenary interview from 2018 Annual Meeting

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 17, 2018 issue of Neurology. In the first segment, Dr. Jason Crowell talks with Dr. Alexis Elbaz about his paper on impulse control disorders in Parkinson disease. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. Jeff Lichtman on connectomics. The interview was recorded at the 2018 AAN Annual Meeting in Los Angeles.

DISCLOSURES: Drs. Crowell and Lichtman reports no disclosures. Dr. Elbaz has received research support from Agence nationale de la recherche (ANR), Agence nationale de sécurité du médicament et des produits de santé, JPND (Joint Programme - Neurodegenerative Disease Research), Institut de santé publique (IRESP), French ministry of agriculture, and Anses (government agency for food and environment safety). Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.

July 10 2018 Issue

Practice guideline update summary: Efficacy and tolerability of new antiepileptic drugs I: Treatment of new-onset epilepsy

Listen

1. Featured Article: Practice guideline update summary: Efficacy and tolerability of new antiepileptic drugs I: Treatment of new-onset epilepsy

2. Lesson of the Week: Functional Disorders

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 10, 2018 issue of Neurology. In the first segment, Dr. Derek Bauer talks with Dr. Jacqueline French about her paper, a summary of a recent practice guideline on the treatment of new-onset epilepsy. In the second part of the podcast, Dr. David Lapides continues the Lesson of the Week discussion on functional disorders with Dr. Jon Stone.

DISCLOSURES: Dr. French has served on scientific advisory boards and consulted for the Epilepsy Foundation, Acadia, Acorda, Adamas, Alexza, Anavex, Axcella Health, Biogen, BioPharm Solutions, Cavion, Cerecor, Cerebral Therapeutics, Concert Pharmaceuticals, Covance, CuroNZ, Eisai, Empatica, Engage, Georgia Regents University, Glaxo Smith-Kline, GW Pharma, J&J Pharmaceuticals, Marinus, MonosolRx, Monteris, Nestle-Health Science, Neurelis, Novartis, Otsuka, Ovid, Pfizer, Pfizer-Neusentis, Sage Therapeutics, Shire, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Ultragenyx, Xenon Pharmaceuticals, Xeris, Zogenix and Zynerba; has received research support from Alexza, Acorda, LCGH, Eisai Medical Research, LCGH, Lundbeck, Neurelis, Pfizer, SK life sciences, Sunovion, Takeda, UCB, Upsher-Smith, Biogen, NINDS (2U01NS038455-11A1), Epilepsy Foundation, and Epilepsy Study Consortium; has received paid travel to present findings at scientific meetings, present at investigators' meetings, attend advisory boards, or give lectures from Epilepsy Study Consortium, Epilepsy Foundation, International League Against Epilepsy, American Academy of Neurology, American Epilepsy Foundation, Adamas, Biogen, Eisai, Engage, GW Pharma, GSK, Novartis, Otsuka, Ovid, Pfizer, Sage, Sunovion, Takeda, UCB, Ultragenyx, Upsher-Smith, Zynerba, Blackfynn Pfizer, Pfizer-Neusentis, Sage, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith,Zogenix, and Zynerba; serves on editorial boards for Lancet Neurology, Neurology Today, and Epilepsy Currents; and serves as President, Epilepsy Study Consortium Chief Scientific Officer, Epilepsy Foundation. Drs. Bauer and Lapides report no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence. 

July 3 2018 Issue

Conscious sedation or local anesthesia during endovascular treatment for acute ischemic stroke 

Listen

1. Featured Article: Conscious sedation or local anesthesia during endovascular treatment for acute ischemic stroke

2. Lesson of the Week: Functional disorders

This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 3, 2018, print issue of Neurology. In the first segment, Dr. Brian Eckerle talks with Dr. Rob van de Graaf about his paper on conscious sedation vs local anesthesia during endovascular treatment for ischemic stroke. For the Lesson of the Week segment, Dr. David Lapides and Dr. Jon Stone continue their discussion of functional disorders.

DISCLOSURES: Drs. Eckerle, van de Graaf, and Lapides report no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence. 

June 12 2018 Issue

Reflections on Translation: Views of Participants in a Multi-Site Canadian CCSVI Clinical Trial

Listen

1. Featured Article: Reflections on Translation: Views of Participants in a Multi-Site Canadian CCSVI Clinical Trial

2. Lesson of the Week: Functional disorders

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 12, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Shelly Benjaminy about her paper on patients’ perspectives from the chronic cerebrospinal venous insufficiency clinical trial in Canada. In the second segment, Dr. David Lapides continues his discussion with Dr. Jon Stone about how to approach functional disorders.

DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Benjaminy has received research support from Canadian Institutes of Health Research [INV-126709], University of British Columbia [Public Scholars Award, Li Tze Fong Memorial Fellowship, Millie and Ralph Drabinsky Graduate Scholarship in Medicine, and Faculty of Medicine Graduate Scholarship], and Stem Cell Network Canada. Dr. Lapides reports no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.

Validation of a simple disease-specific quality of life measure for diabetic polyneuropathy; the CAPPRI

Listen

1. Featured Article: Validation of a simple disease-specific quality of life measure for diabetic polyneuropathy; the CAPPRI

2. Lesson of the Week: Functional disorders

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 5, 2018, print issue of Neurology. In the first segment, Dr. Alex Menze interviews Dr. Kelly Gwathmey about her paper on a new quality of life measure for diabetic polyneuropathy. For the second segment, Dr. David Lapides speaks with Dr. Jon Stone about updates in approaching functional disorders in the clinic.

DISCLOSURES: Dr. Menze, Dr. Gwathmey, and Dr. Lapides report no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.

May 29 2018 Issue

Long-term Neuropsychological Outcome Following Pediatric Anti-NMDAR Encephalitis

Listen

1. Featured Article: Long-term Neuropsychological Outcome Following Pediatric Anti-NMDAR Encephalitis

2. What’s Trending: Amateur fundus photography

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 29, 2018 issue of Neurology. In the first segment, Dr. David Lapides talks with Dr. Maarten Titulaer about his paper on long-term neuropsychological outcome following pediatric anti-nmdar encephalitis. Next, Dr. Roy Strowd talks with Dr. Saman Zafar about her paper on amateur fundus photography for our “What’s Trending” feature of the week. Disclosures can be found at Neurology.org.

DISCLOSURES: Dr. Titulaer serves on the editorial board of Neurology: Neuroimmunology & Neuroinflammation; filed a patent for "methods for typing neurological disorders and cancer, and devices for use therein" specifically about diagnostics for anti-GABAB receptor antibodies and KCTD antibodies; and has received research support from Medimmune LLC, Guidepoint Global LLC, Novartis, Euroimmun AG, the Netherlands Organisation for Scientific Research, an ErasmusMC fellowship, and the Dutch Epilepsy Foundations. Dr. Strowd serves on the editorial board for Neurology (Resident & Fellow section); and has received research support from the Wake Forest School of Medicine Center for Translational Sciences Award, the KL2 Career Development Award, and the American Academy of Neurology. Dr. Lapides and Dr. Zafar report no disclosures.

May 22 2018 Issue

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer Disease

Listen

1. Featured Article: ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer Disease

2. What’s Trending: Epilepsy Birth Control Registry

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 22, 2018, print issue of Neurology. In the first segment, Dr. Jeff Burns talks with Dr. Jeffrey Cummings about results from the ABBY clinical trial on crenezumab as a potential treatment for mild to moderate Alzheimer Disease. For the “What’s Trending” segment, Dr. Katherine Zarroli interviews Dr. Andrew Herzog about the Epilepsy Birth Control Registry (http://www.epilepsybirthcontrolregistry.org).

DISCLOSURES: The participants report no disclosures.

May 15 2018 Issue

Ask a Neurologist: What Primary Care Providers ask, and reducing referrals through eConsults

Listen

1. Featured Neurology^® Clinical Practice Article: Ask a Neurologist: What Primary Care Providers ask, and reducing referrals through eConsults

2. What’s Trending: Update on arboviruses

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 15, 2018, print issue of Neurology^®. In the first segment, Dr. Heather Harle interviews Drs. Ana Bradi and Erin Keely about their paper on implementing an eConsult service between primary care providers and neurologists at the Ottawa Hospital. For the “What’s Trending” segment, Dr. Amanda Piquet and Dr. Daniel Pastula discuss what every neurologist should know about mosquito- and tick-borne disease.

DISCLOSURES: Dr. Piquet and Dr. Pastula report no disclosures.

May 8 2018 Issue

Factors associated with treatment delays in pediatric refractory convulsive status epilepticus 

Listen

1. Featured Article: Factors associated with treatment delays in pediatric refractory convulsive status epilepticus

2. What’s Trending: Focused ultrasound for treating tremor

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 8, 2018 issue of Neurology. In the first segment, Dr. Erika Axeen talks with Dr. Iván Fernández about his paper on factors that influence treatment delays in pediatric refractory convulsive status epilepticus. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Jeff Elias on two recent articles published in the New England Journal of Medicine regarding focused ultrasound treatment for tremor.

DISCLOSURES: Drs. Axeen and Crowell report no disclosures. Dr. Fernández has received research support from Epilepsy Research Fund, Fundación Alfonso Martín Escudero (Grant for the study of Epileptic Encephalopathies), and HHV6 Foundation. Dr. Elias reports grant support from InSightec, the BIRD Foundation, and the Focused Ultrasound Foundation.

May 1 2018 Issue

Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease 

Listen

1. Featured Article: Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease

2. What’s Trending: Drug pricing

This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 1, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Matthew Barrett about his paper on predictors of psychosis in Parkinson disease. For the “What’s Trending” segment, Dr. Ted Burns discusses drug pricing with journalist Ike Swetlitz.

DISCLOSURES: Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Barrett has received research support from Axovant Sciences, Inc. (clinical trial site PI), Azevan Pharmaceuticals (clinical trial site PI), Merck Sharp & Dohme Corp. (Clinical trial site PI), Biogen (clinical trial site PI), Virginia Center of Alzheimer´s and Related Diseases Research Award Fund (PI), U.S. Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Career Progress Award (PI), and NIH (clinical trial site PI).Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Mr. Swetlitz is a reporter for StatNews.

April 24 2018 Issue

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis 

Listen

1. Featured Article: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

2. What’s Trending: Global, regional, and national burden of neurological disorders during 1990–2015 (from Lancet Neurology)

This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 24, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Alexander Rae-Grant about the AAN Practice Guideline on disease-modifying therapies for adults with multiple sclerosis. For the “What’s Trending” segment, Dr. Jason Crowell interviews Dr. Theo Vos about findings from the Global Burden of Diseases, Injuries, and Risk Factors Study and the growing need for clinicians with neurologic expertise.

DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Rae-Grant has served on the Neurology Evidence Review Team, 2011-2018; receives publishing royalties from Handbook of Multiple Sclerosis (Springer Healthcare, 2010), Comprehensive review of clinical neurology, (Wolters Kluwer, 2012), 5 minute consult in neurology (Wolters Klower, 2012), Comprehensive review of clinical neurology second edition ( LWW, 2016), Ultimate review of neurology (DEMOS 2016), and Multiple Sclerosis and Related disorders (DEMOS, 2014); edits neurology chapters for Dynamic Medical, an online text book of medicine which is funded via library subscriptions; was involved in a clinical trial of biotin for multiple sclerosis with MedDay (no personal remuneration); and receives research support from NIH (grant #A6022304). Dr. Crowell reports no disclosures.

View All Podcasts  Subscribe
 

April 17 2018 Issue

Clinical Reasoning: A young woman with symmetric weakness and behavioral disturbance 

Listen

1. Featured Article: Clinical Reasoning: A young woman with symmetric weakness and behavioral disturbance

2. What’s Trending: DEFUSE 3 trial results on thrombectomy vs. standard therapy alone for ischemic stroke

This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 17, 2018, print issue of Neurology. In the first segment, Dr. Dan Ackerman talks with Dr. Jon Rosenberg about the differential diagnosis of a young patient with symmetric weakness, behavioral changes, and bilateral infarcts. For the “What’s Trending” segment, Dr. Nicole Chiota-McCollum speaks with Dr. Gregory Albers about findings from the DEFUSE 3 clinical trial.

DISCLOSURES: Dr. Ackerman, Dr. Rosenberg, and Dr. Chiota-McCollum report no disclosures. Dr. Albers has served on a steering committee for Lundbeck and Covidien; serves on the editorial board for Stroke; holds a patent for RAPID software for MRI and CTP analysis of diffusion and perfusion data; has consulted for Astra Zeneca, Biogen, and iSchemaView; holds stock in iSchemaView; and has received research support from NINDS.

April 10 2018 Issue

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD 

Listen

1. Featured Article: Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD

2. Neurology Today: 2017 Top Advances

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 10, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Riley Bove about her Neurology: Neuroimmunology & Neuroinflammation paper on rituximab treatment before and during pregnancy for patients with multiple sclerosis and NMOSD. For the second segment, Dr. Andy Southerland speaks with Dr. Joseph Safdieh on the Neurology Today editorial selections for the top research advances in 2017.

DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Safdieh has served on scientific advisory board for Upsher Smith; receives publishing royalties from Rubin MP, Safdieh JE. Netters Concise Neuroanatomy (Elsevier 2007); and serves as Editor-in-Chief of Neurology Today.

April 3 2018 Issue

The Mitochondrial Disease Patients’ Diagnostic Odyssey: Results of A Survey 

Listen

1. Featured Article: The Mitochondrial Disease Patients’ Diagnostic Odyssey: Results of A Survey

2. What's Trending: Teen concussion and early tauopathy

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 3, 2018, print issue of Neurology. In the first segment, Dr. Jason Crowell talks with Drs. John L.P. Thompson and Michio Hirano about their Neurology: Genetics paper on the long journey to diagnosis for patients with mitochondrial disease. For the “What’s Trending” segment, Dr. Jeff Ratliff speaks with Dr. Lee Goldstein about teen concussion and early tauopathy.

DISCLOSURES: Dr. Crowell reports no disclosures. Dr. Thompson has recieved research support from Novartis, NIH/NINDS (1U54 NS078059-06), NIEHS (P30 ES009089-15), and the FDA (UFDSP00011270). Dr. Hirano has received honoraria for serving on advisory boards of Stealth Biotherapeutics, Sarepeta, and Biogen; received received travel funds from the American College of Medical Genetics; has served as Nerve and Muscle editor of Current Neurology and Neuroscience Reports (2002-present); holds Rare Pediatric Disease (RPD) and Orphan Drug Designations (ODD) for deoxynucleoside therapy for mitochondrial DNA depletion syndrome including TK2 deficiency; received honoraria as a member of the Speakers' Bureau of Athena Diagnostics; and received research support from Santhera Pharmaceutical, Edison Pharmaceutical, National Institutes of Health (U54NS078059, R01HD056103 RC1NS070232 P01HD032062), Muscular Dystrophy Association (MDA) USA and Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF). Dr. Goldstein is a consultant for Rebiscan, Inc. Dr. Ratliff has received a speaker honorarium from Haverford College.

March 27 2018 Issue

IgLON5 antibody: Neurological Accompaniments & Outcomes in 20 patients 

Listen

1. Featured Article: IgLON5 antibody: Neurological Accompaniments & Outcomes in 20 patients

2. Health policy update - Coding, Reimbursement & Quality Payment Program

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 27, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Andrew McKeon about his Neurology: Neuroimmunology & Neuroinflammation paper describing IgLON5 autoimmunity. For the “What’s Trending” segment, Dr. Jason Crowell speaks with Luana Ciccarelli and Amanda Napoles on regulatory updates in coding and reimbursement, MACRA, and tips for private practitioners on participating in the Quality Payment Program.

DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. McKeon has patent applications pending for GFAP and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; has consulted for Grifols, Medimmune, Inc., and Euroimmun (but did not receive personal compensation for these activities); and has received research support from Medimmune, Inc. and Euroimmun. Dr. Crowell reports no disclosures. Luana Ciccarelli and Amanda Napoles are employed by the American Academy of Neurology.

March 20 2018 Issue

Molecular genetic testing for hereditary ataxia – What every neurologist should know 

Listen

1. Featured Article: Molecular genetic testing for hereditary ataxia – What every neurologist should know

2. What’s Trending: Recent changes to Maintenance of Certification requirements

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 20, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Thomas Bird about his Neurology: Clinical Practice paper on the benefits and limitations of exome sequencing to identify hereditary ataxias. For the “What’s Trending” segment, Dr. Stacey Clardy with Dr. Laurie Gutmann about recent updates to the Maintenance of Certification requirements and tips to ease the process for neurologists.

DISCLOSURES: Dr. Bird serves on the editorial board for GeneReviews.org; holds patents for genetic testing technology for CMT1C and SCA14; and has received research support from the Department of Veterans' Affairs (Merit Research Grant, PI, 2009-2017). Dr. Gutmann serves on the editorial board for Up-to-Date Online (Hypokalemic and Hyperkalemic Periodic Paralysis); and has recieved research support from Alexion Pharmaceuticals, Inc. and the NIH (U01 NS069498-01 A1, 3P50NS044283-07S1, U01 NS026835-01A1, U01 NS058728-01, and U01 NS077179-01). Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).

March 13 2018 Issue

Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence 

Listen

1. Featured Article: Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence

2. What’s Trending: Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 13, 2018, issue of Neurology. In the first segment, Dr. Mark McAllister talks with Dr. Luciano Sposato about their paper on the relationship between atrial fibrillation detection and ischemic stroke recurrence. For the “What’s Trending” segment, Dr. Ted Burns speaks with Dr. Mark Keegan and Dr. Nick Zalewski about their paper on idiopathic transverse myelitis and myelopathy diagnoses.

DISCLOSURES: Dr. Sposato has received travel or speaker honoraria from Boehringer Ingelheim and Pfizer; serves on the Editorial Board for Neurology; and has received research support from Kathleen & Dr Henry Barnett Research Chair in Stroke Research, Boehringer Ingelheim (salary support for a fellow), Edward and Alma Saraydar Neurosciences Fund, Opportunities Fund of the Academic Health Sciences Centre Alternative Funding Plan of the Academic Medical Organization of Southwestern Ontario, and Boehringer Ingelheim. Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press, 2016); has consulted for Novartis, Bristol Meyers Squibb, and Bionest; and has received research support from Biogen (ARISE study). Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. McAllister and Dr. Zalewski report no disclosures.

March 6 2018 Issue

Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era 

Listen

1. Featured Article: Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era

2. What’s Trending: Sleep architecture and risk of dementia

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 6, 2018, issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Raed Alroughani about his article on relapse recurrence during pregnancy in women with multiple sclerosis. In the second part of the podcast, you’ll hear Dr. Jeff Burns interviews Dr. Sudha Seshadri about sleep and dementia risk.

DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Alroughani served in scientific advisory boards of Novartis, Bayer, Merck-Sorono, Roche, Biogen, Sanofi-Geznyme; has received speaker and travel honoraria from Novartis, Bayer, Merck-Sorono, Biogen, Roche, Sanofi-Genzyme and GSK; and has received research grants from Biogen, Novartis and Sanofi-Genzyme. Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001). Dr. Seshadri serves on editorial boards for Journal of Alzheimer's Disease, Stroke, and Neurology; and has received research support from NIA (AG008122, AG033040, AG049505, AG033193, AG049607, AG054076).

February 27 2018 Issue

Interdisciplinary Response to Contemporary Concerns about Brain Death Determination 

Listen

1. Featured Article: Interdisciplinary Response to Contemporary Concerns about Brain Death Determination

2. What’s Trending: Gene Drive, part 2

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 27, 2018 issue of Neurology. In the first segment, Dr. Andy Schomer talks with Dr. Ariane Lewis about her paper on the determination of brain death. In the second part of the podcast, Dr. Ted Burns speaks with Dr. Kevin Esvelt for part two of the discussion on gene drives (the first of these segments aired in the Feb. 20 episode). 

DISCLOSURES: Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. All other participants report no disclosures.

February 20 2018 Issue

Intravenous thrombolysis and platelet count

Listen

1. Featured Article: Intravenous thrombolysis and platelet count

2. What’s Trending: Gene Drives, part I

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 6, 2018, issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Henrik Gensicke about his article on the effect of platelet count on bleeding risk and mortality in stroke patients treated with IV thrombolysis. In the second part of the podcast, you’ll hear the first part of Dr. Ted Burns’ interview with Dr. Kevin Esvelt about gene drives.

DISCLOSURES: Dr. Barrett serves on the editorial board of Neurology and Neurohospitalist; has received research/grant support from the National Institute of Neurological Disorders and Stroke for serving on the executive committees of the CREST-2 and SHINE clinical trials; and receives publishing royalties from Wiley Blackwell. Dr. Gensicke receives research support from Swiss National Science Foundation (33CM30-124119 and P300PB_161071). Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. Esvelt reports no disclosures.

February 13 2018 Issue

Medical Retirement from Sport after Concussions: A practical guide for a difficult discussion

Listen

1. Featured Article: Medical Retirement from Sport after Concussions: A practical guide for a difficult discussion

2. What’s Trending: CGRP drugs and treatment of migraine

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 13, 2018 issue of Neurology. In the first segment, Dr. Jason Crowell talks with Dr. James Noble about his Neurology® Clinical Practice paper on athletes who retire from sport following concussion. In the second part of the podcast, Dr. Tesha Monteith focuses her interview with Dr. Peter Goadsby on CGRP and migraine.

DISCLOSURES: Dr. Crowell reports no disclosures. Dr. Noble received travel honoraria for the Big 10/Ivy League concussion summit; has a pending patent for a real-time concussion diagnostic tool; has consulted with Prophase, LLC; has received research support from NIH (U54 NS081765, R01 NS067443, R01AG054536, T35 AG044303); and holds stock options in BATS-TOI. Dr. Goadsby has consulted for Akita, Allergan, Amgen, Autonomic Technologies Inc, Avanir, Cipla, Dr Reddy's Laboratories, Eli-Lilly, Electrocore, eNeura, Pfizer, Scion, Teva, and Trigemina; serves on editorial boards for NEJM Journal Watch, and Neurology Up-to-Date; receives publishing royalties for Mechanism and Management of Headache (Elsevier 2005); holds stock options in Trigemina Inc.; and receives research support from Amgen, and Eli-Lilly. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.

February 6 2018 Issue

Burnout, Wellness, and the Future of Our Profession

Listen

Featured Article: Burnout, Wellness, and the Future of Our Profession

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 6, 2018, issue of Neurology. This week we are featuring an extended interview as Dr. Ted Burns talks with Dr. Terry Cascino about his special address on burnout and the future of neurology.

DISCLOSURES: Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. Cascino is the immediate past president of the American Academy of Neurology.

January 30 2018 Issue

Racial disparities in refusal of stroke thrombolysis in Chicago

Listen

1. Featured Article: Racial disparities in refusal of stroke thrombolysis in Chicago

2. Lesson of the Week: Emergency management of migraine

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 30, 2018, issue of Neurology. In the first segment, Dr. Jennifer Majersik talks with Dr. Scott Mendelson about his paper on differences in tPA refusal in black vs non-black patients with acute ischemic stroke. In the second part of the podcast, Dr. Teshamae Monteith focuses her Lesson of the Week interview with Dr. Benjamin Friedman on IV prochlorperazine plus diphenhydramine vs IV hydromorphone for emergency migraine treatment.

DISCLOSURES: Dr. Majersik serves on the editorial board for Neurology; receives research support from National Institutes of Health (grant U10 NS086606); and served as an expert witness for FAVROS, LCC. Dr. Mendelson has received travel honoraria from Medtronic; has received research support from University of Chicago and Institute of Medicine of Chicago. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Friedman reports no disclosures. 

January 23 2018 Issue

Collateral response modulates the time–penumbra relationship in proximal arterial occlusions

Listen

1) Featured Article: Collateral response modulates the time–penumbra relationship in proximal arterial occlusions

2) Lesson of the Week: Migraine and neuromodulation

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 23, 2018, issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Smriti Agarwal about her paper on collateral circulation in proximal arterial occlusions and extending the scope of thrombolytic therapy. In the second part of the podcast, Dr. Teshamae Monteith focuses her Lesson of the Week interview with Dr. Stewart Tepper on acute and preventative neuromodulation treatment for migraine.

DISCLOSURES: Dr. Barrett serves on the editorial board of Neurology and Neurohospitalist; has received research/grant support from the National Institute of Neurological Disorders and Stroke for serving on the executive committees of the CREST-2 and SHINE clinical trials; and receives publishing royalties from Wiley Blackwell. Dr. Agarwal reports no disclosures. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Tepper is a member of the board for the American Headache Society and has been a consultant for or participated on a paid advisory board for Acorda Therapeutics, Inc; Alder BioPharmaceuticals, Inc; Allergan plc; Amgen, Inc; Avanir Pharmaceuticals, Inc; BioVision, Inc; Charleston Laboratories, Inc; Dr. Reddy’s Laboratories, Ltd; electroCore, LLC; eNeura, Inc; Eli Lilly and Company; GLG Pharma, LLC; Guidepoint Inc, LLC, Ltd; Kimberly-Clark Corporation; Pernix Therapeutics Holdings, Inc; Pfizer, Inc; Scion NeuroStim, LLC; Teva Pharmaceutical Industries, Ltd; and Zosano Pharma, Corp. 

January 16 2018 Issue

Practice guideline update summary: Mild cognitive impairment

Listen

1) Featured Article: Practice guideline update summary: Mild cognitive impairment

2) Lesson of the Week: Migraine and hormones

This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 16, 2018, print issue of Neurology. In the first segment, Dr. Jeff Burns talks with Dr. Ronald Petersen about the updated 2001 AAN guideline on prevalence, prognosis, and treatment of MCI. For the Lesson of the Week, Dr. Teshamae Monteith speaks with Dr. Jelena Pavlovic about the association between hormones and migraine. 

DISCLOSURES: Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001). Dr. Petersen receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003); has consulted for Roche Incorporated, Merck, Genentech, and Biogen; and receives research support from National Institute on Aging (U01-AG006786, P50-AG016574, U01-AG024904, and U01-AG016976). Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Pavlovic has received consulting honoraria and travel support from Allergan, Inc. and travel/conference registration support from The American Headache Society. 

January 9 2018 Issue

Quality improvement in neurology: Child neurology quality measure set

Listen

1) Featured Article: Quality improvement in neurology: Child neurology quality measure set 

2) Lesson of the Week: Update on chronic migraine risk factors, management, and treatment

This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 9 issue of Neurology. In the first segment, Dr. Adam Numis talks with Dr. Jeffrey Buchhalter and Dr. Anup Patel about their quality measure set executive summary article regarding child neurology. For the “Lesson of the Week” segment, Dr. Tesha Monteith speaks with Dr. Stephen Silberstein about chronic migraine.

DISCLOSURES: Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section; has received speaker honorarium from LivaNova; and has received research support from American Academy of Neurology, Clinical Research Training Fellowship in Epilepsy, 2017-2019, and American Epilepsy Society, Research and Training Fellowships for Clinicians, 2017-2018. Dr. Bucchalter has served on advisory and safety monitoring boards for NIH, NINDS, Observational Safety Monitoring Board for NIH, and the Charlie Foundation; has received travel and speaker honoraria from AAN, Eisai Co. Ltd., Child Neurology Society, Lundbeck, and Upsher-Smith Labs; serves on the editorial board for Pediatric Neurology; has consulted in the past with Lundbeck Inc., Eisai Co. Ltd., UCB, and Upsher-Smith; and has received research support from Alberta Health Services. Dr. Patel has served on scientific advisory board for UCB Pharma; has served as book and associate editor for Journal of Child Neurology; has consulted for Greenwich Biosciences, LivaNova, and Supernus; and has received research support from Greenwich Biosciences, Brain Sentinel, Upsher Smith Pharmaceuticals, LivaNova, Pediatric Epilepsy Research Foundation (PERF), and American Academy of Neurology (AAN). Dr. Silberstein has served on scientific advisory boards for Alder, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Medscape, Medtronic, Mitsubishi Tanabe, Neuralieve, NINDS, Pfizer, Supernus, Teva, Curelator, Depomed, Dr. Reddy's Laboratories, Lilly, and Trigemina; has served on editorial boards for Cephalalgia, Current Pain and Headache Reports, CNS Drugs, Topics in Pain Management, and Neurology; has consulted for Allergan, Amgen, eNeura, ElectroCore Medical, Mitsubishi Tanabe, Medtronic, Neuralieve, Pfizer, Supernus, and Teva; served on speaker's bureaus in the past for Allergan, Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck; and has received research support from GlaxoSmithKline, Allergan, Merck, Novartis, NIH, Neurolieve, MAP, Endo, Amgen, ElectroCore, Avanir, NIH, AHS, and IHS. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.

January 2 2018 Issue

Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy

Listen

1) Featured Article: Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy

2) What’s Trending: Clinical Trials in Alzheimer Disease

This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Carlos Pardo about his paper on clinical biomarkers and differential diagnosis of myelitis. For the “What’s Trending” segment, Dr. Ted Burns speaks with journalist Damian Garde about the recent Clinical Trials in Alzheimer Disease conference.

DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Pardo has served on scientific advisory board for the Transverse Myelitis Association; has received research support from Accorda Pharmaceuticals, Chugai Pharmaceutical Co. LTD, Medimmune, NIH/NINDS (R21NS076381, R01NS055628, R21TW0009741, P30MH075673, 1R01HL130649-01), and the Bart McLean Neuroimmunology Fund from the Transverse Myelitis Association. Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Mr. Garde reports no disclosures. 

December 12 2017 Issue

Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy

Listen

1) Neurology: Neuroimmunology & Neuroinflammation: Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy

2) What’s Trending: R&F section update with Dr. Roy Strowd and highlighted Clinical Reasoning case

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the December 12, 2017 issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Takahiro Iizuka about his paper on diagnosis and treatment of new-onset refractory status epilepticus (NORSE). In the second part of the podcast, Dr. Jeff Ratliff focuses his interview with Dr. Roy Strowd on a highlighted Clinical Reasoning case from the new “Resident & Fellow Rounds” feature debuting in 2018.

DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Langer-Gould has received research support from Biogen, Roche, NIH, PCORI, and the National Multiple Sclerosis Society. Dr. Iizuka serves on editorial boards for Current Treatment Options in Neurology and Rinsho Shinkeigaku (Clinical Neurology), and has received research support from Mitsubishi Tanabe Pharma Corporation (MTPS20160504012) and the Japan Epilepsy Research Foundation (JERFTENKAN 17002). Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Strowd serves on the editorial board of Neurology (Resident & Fellow section); and has received research support from the Wake Forest School of Medicine Center for Translational Sciences Award, the KL2 Career Development Award, and the American Academy of Neurology. 

No CME this week: We do not offer CME for interviews about articles from Neurology® Clinical Practice (including Practice Current), Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation because these are currently not CME-eligible journals.

December 5 2017 Issue

Long-term benefit of enzyme-replacement therapy in Pompe disease: A 5-year prospective study

Listen

1) Long-term benefit of enzyme-replacement therapy in Pompe disease: A 5-year prospective study

2) What’s Trending: ACTH or prednisolone for infantile ataxia

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the December 5, 2017 issue of Neurology. In the first segment, Dr. Kelly Gwathmey talks with Dr. Nadine van der Beek about her paper on enzyme-replacement therapy in Pompe disease. In the second part of the podcast, Dr. Ted Burns focuses his interview with Dr. John Mytinger on the topic of ACTH or prednisolone for infantile ataxia.

DISCLOSURES: Dr. Gwathmey reports no disclosures. Dr. van der Beek has received speaker honoraria from Sanofi-Genzyme (paid to to Erasmus MC for further research purposes); and has received research support from Sanofi-Genzyme, Colciencias, ZonMW - the Netherlands Organization for Health Research and Development, the Prinses Beatrix Spierfonds, SSWO – Sophia Children’s Hospital Foundation, and TKI-Health Holland. Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. Mytinger reports no disclosures. 

Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study

Listen

1) Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study

2) What’s Trending: Neurology paper on breast feeding, ovulatory years, and risk of multiple sclerosis

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 28, 2017 issue of Neurology In the first segment, Dr. Jeff Burns talks with Dr. Keenan Walker about his paper on the association between systemic inflammation and brain volume over time. For our What’s Trending segment, Dr. Stacey Clardy focuses her interview with Dr. Annette Langer-Gould about her recent Neurology article on breast feeding, ovulatory years, and risk of multiple sclerosis.

DISCLOSURES: Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001) Dr. Walker has received research support from the National Institute of Aging (AG027668, postdoc fellow, 2016-17). Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Langer-Gould has received research support from Biogen, Roche, NIH, PCORI, and the National Multiple Sclerosis Society. 

November 21 2017 Issue

Multiparametric MRI changes persist beyond recovery in concussed adolescent hockey players

Listen

1) Multiparametric MRI changes persist beyond recovery in concussed adolescent hockey players

2) Neurology Today® paper on the increase in gabapentinoid prescription

In the first segment, Dr. Ted Burns talks with Dr. Kathryn Manning and Dr. Ravi Menon about their paper regarding the effects of concussion on adolescent hockey players. In the second part of the podcast, Dr. Burns focuses his interview with Dr. Christopher Goodman about a recent Neurology Today article discussing the increase in gabapentinoid prescriptions. 

DISCLOSURES: Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. Manning reports no disclosures. Dr. Menon has served on the scientific advisory board of International Initiative for Traumatic Brain Injury Research (NIH/EU/CIHR); has served on the editorial boards of NeuroImage, Journal of Neurophysiology, Scientific Reports, and Tomography; has received research support from Siemens Healthineers, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Canada First Research Excellence Fund, and Brain Canada Foundation; and has received royalty payments from Siemens Healthcare for US Patent 8,193,812. Dr. Goodman reports no disclosures. 

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

November 14 2017 Issue

Infliximab for the treatment of central nervous system sarcoidosis: A multi-institutional series

Listen

1) Infliximab for the treatment of central nervous system sarcoidosis: A multi-institutional series

2) What’s Trending: Sonic traumatic brain injury

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 14, 2017 issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Siddharama Pawate and Dr. Jeff Gelfand about their paper on infliximab for treatment of central nervous system sarcoidosis. In the second part of the podcast, Dr. Alex Menze focuses his interview with Dr. Jeffrey Kim on the recent speculation around sonic traumatic brain injury.

DISCLOSURES: Dr. Gelfand has served on scientific advisory boards for Genentech; has received compensation for consulting with Genentech; has received research support from Quest Diagnostics, Genentech, MedDay, and NIH National Center for Advancing Translational Sciences (KL2TR000143); and has received compensation for serving as expert witness in medical-legal consulting. Dr. Pawate has served on scientific advisory board for Biogen, and has received research support from Biogen. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). All other participants report no disclosures. 

November 7 2017 Issue

This variant alters protein function, but is it pathogenic?

Listen

1) This variant alters protein function, but is it pathogenic? (Neurology® Genetics)

2) What’s Trending: PFO Updates

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 7, 2017 issue of Neurology. In the first segment, Dr. Michelle Mauermann talks with Dr. Massimo Pandolfo about his recent Neurology® Genetics editorial, entitled “This variant alters protein function, but is it pathogenic?”. In the second part of the podcast, Dr. Nicole Chiota focuses her interview with Dr. Steven Messe on recent PFO/stroke updates.

DISCLOSURES: Dr. Mauermann serves on the editorial board of Mayo Clinic Proceedings; receives publishing royalties from Oxford, and has received research support from Ionis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals. Dr. Pandolfo has served on the scientific advisory boards of Apopharma and Voyager Therapeutics; has served on the editorial boards of Acta Neurologica Belgica, Orphanet Journal of Rare Diseases, and Neurology Genetics; is co-holder of a patent for Direct molecular diagnosis of Friedreich’s ataxia; has been a consultant for Biomarin and UCB; has received research support from Biomarin, Fonds National de la Recherche Scientifique (Belgium), Offrez-moi-la-lune, Friedreich's Ataxia Research Alliance, and Association Belge contre les Maladies neuro-Musculaires, and receives royalty payments from Athena Diagnositcs for a Friedreich's ataxia diagnostic test. Dr. Chiota reports no disclosures. Dr. Messe has served on the scientific advisory board of the Yale University Cardiovascular Research Group; has received travel funding from the American Academy of Neurology; has received publishing royalties from Up To Date; has been a consultant for Claret Medical; and has received research support from WL Gore, Glaxo Smith Kline, Bayer, Mallinkrodt, and NIH. 

Delayed Recall - November 2017

Immunotherapy

Listen

This month’s Delayed Recall episode features Dr. Stacey Clardy’s Lesson of the Week interviews on the topic of immunotherapy, which originally aired in July 2017. In the first interview, Dr. Clardy speaks with Dr. Dennis Bourdette about new immunotherapies in neurology. This interview first appeared in the July 4 episode. In the interview from July 11, Dr. Clardy continues the discussion about new immunotherapies with Dr. Jeffrey Cohen. The third interview, from the July 18 episode, features Dr. Clardy speaking with Dr. Emmanuelle Waubant about immunotherapy as it applies to multiple sclerosis patients. To conclude this episode, we offer Dr. Clardy’s interview with Dr. Anne Cross, in which they talk about immunosuppressants in Neurology; this interview was part of the July 25 episode.

View All Podcasts Subscribe